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Sir,
Dr Alliot and Barrios pointed out that our results have been
obtained in selected elderly patients. We did not evaluate the
number of elderly patients who were candidates for oxaliplatin or
irinotecan chemotherapy but did not receive it. Nevertheless, two
French studies estimate that only 8–17% of patients over 75 years
with advanced colorectal cancer received palliative chemotherapy
(Mitry et al, 2003; Navazesh et al, 2003). Few elderly patients are
referred to the oncologist for various reasons (Mahoney et al,
2000). In our study, the patients have few comorbidities and we
concluded that chemotherapy with oxaliplatin or irinotecan is
feasible in fit elderly patients.
The overall rate of grade III and IV toxicity appears too high
to be acceptable for Dr Alliot and Barrios. Nevertheless, only
17% of the patients stopped the treatment because of the
toxicity and no toxic death occurred after the 545 cycles
analysed. Moreover, the observed toxicity rate was similar to
that observed in younger patients treated with these drugs
in a palliative situation (de Gramont et al, 2000; Douillard
et al, 2000). The toxicity of irinitocan is related to the
administration schedule even in young patients. The two phase
II studies cited by Alliot and Barrios (Rougier et al, 1997;
Rothenberg et al, 1999) investigated weekly or 3-weekly irinotecan
monotherapy schedule. The weekly regimen is more toxic than the
biweekly schedule and dose reduction is less frequent in the latter
(Douillard et al, 2000).
The mean haemoglobin level was in the lower bound of the
normal range, creatinin clearance was reduced in our patients and
especially in those aged over 80, as it is presented in Table 1.
Bilirubin was increased in 9% of the patients and alkaline
phosphatase increased more than 2 N in 15% of the patients.
Nevertheless, neither haemoglobin level, creatinin clearance,
alkaline phosphatase nor bilirubin level were associated with
increased toxicity in our patients (data not shown). It must be
pointed out that patients with a Charlson score 42 had more
treatment interruption for toxicity.
We agree with Dr Alliot and Barrios that albumin level and
polypharmacy may interfere with chemotherapy and that a dose
reduction should be done in some cases. In our study, only six
(9%) patients had a dose reduction from the first cycle, a severe
toxicity occurred in only one (17%) of these patients. Early toxicity
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reduction occurred in eight (12%) patients. So, it appears that not
all elderly patients will benefit from a systematic initial dose
reduction. Nevertheless, the predictive factors for adaptation could
not be drawn from this study.
A recent study demonstrated that the willingness of elderly
patients to be treated with chemotherapy is high even in
French patients and must not be underestimated (Extermann
et al, 2003). The only way to improve the management and
prognostics of elderly patients with cancer and to evaluate
the safety and efficiency of chemotherapy in this population
is to perform specific trials. Two prospective randomised
studies specific for elderly patients with advanced colorectal
cancer have just started in France, initiated by the ‘Fe ´de ´ration
Francophone de Cance ´rologie Digestive’. So, we invite our
French colleagues to join us and include their patients in these
studies in order to precise the best therapeutic strategy for elderly
patients.
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